Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)
Trial details
- Registry ID
- NCT02591862
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as rEV576; rVA576
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)NCT02591862 | AKARI Therapeutics | Phase 2 | Completed | 2018-03-20Actual |
| Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 PolymorphismsNCT03427060 | AKARI Therapeutics | Phase 2 | Completed | 2018-11-15Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |